Trial Search Results

PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)

The study aims to determine the safety and efficacy of povidone-iodine (PVP-I) containing nasal sprays as compared to isotonic saline nasal sprays in COVID-19 positive patients. The primary outcome measure is SARS-CoV-2 viral titers in the nasal cavity and nasopharynx. In vitro studies have shown PVP-I to be highly virucidal against the viruses which cause SARS and MERS. Additionally, clinical studies have shown PVP-I saline sprays to be well tolerated in human subjects. PVP-I oral rinses and sprays have been trialed as methods to reduce the incidence and symptoms of viruses which cause the "common cold."

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Drug: Povidone-Iodine 2%
  • Drug: Povidone-Iodine 0.5%
  • Drug: Isotonic saline 0.9%


Phase 1/Phase 2


Inclusion Criteria:

   - Diagnosis of COVID-19 by lab test within 5 days of study participation

Exclusion Criteria:

   - Allergy to "iodine," shellfish, or food dye

   - Receiving intranasal steroids

   - Sinus surgery within 30 days of beginning the study

   - Intubated at the time of enrollment

   - Pregnancy

   - Participation in other COVID-19 studies - to be determined on a case by case basis

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Peter H Hwang, MD
Not Recruiting